Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice

Journal of Oncology Pharmacy Practice

Volumn 17, Issue 3, 2011, Pages 197-202

  Agostino, Nicole M ^a   Chinchilli, Vernon M ^a   Lynch, Christopher J ^a   Koszyk Szewczyk, Anita ^a   Gingrich, Rebecca ^a   Sivik, Jeffrey ^a   Drabick, Joseph J ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

dasatinib; diabetes; glucose; imatinib; sorafenib; sunitinib

Indexed keywords

DASATINIB; GLUCOSE; IMATINIB; INSULIN; NILOTINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STEM CELL FACTOR; SUNITINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BLOOD GLUCOSE; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INDOLES; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASMS; PENNSYLVANIA; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053339992     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155210378913     Document Type: Article

References (17)

1. Garcia A. Small molecules: big changes in the cancer treatment paradigm. J Pharm Prac 2008 ; 21 (1). 17-35. (Pubitemid 351464539)
2. Billemont B., Medioni J., Taillade L., et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2008 ; 99: 1380-1382.
3. Veneri D., Franchini M. and Bonora E. Imatinib and regression of type 2 diabetes. NEJM 2005 ; 352 (10). 1049-1050.
4. Breccia M., Muscaritoli M., Aversa Z., et al. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol 2004 ; 22 (22). 4653-4655. (Pubitemid 41185138)
5. Breccia M., Muscaritoli M., Cannella L., et al. Fasting glucose improvement under dasatinib treatment in accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res 2008 ; 32: 1626-1628.
6. Haap M., Gallwitz B., Thamer C., et al. Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor. J Endocrinol Invest 2007 ; 30 (8). 688-692. (Pubitemid 350104100)
7. Akin C. and Metcalfe DD The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 2004 ; 114: 13-19. (Pubitemid 39005112)
8. Rachdi L., El Ghazi L., Bernex F., et al. Expression of the receptor tyrosine kinase KIT in mature β-cells and in the pancreas in development. Diabetes 2001 ; 50: 2021-2028. (Pubitemid 33643668)
9. Krishnamurthy M., Ayazi F., Li J., et al. c-Kit in early onset of diabetes: a morphological and functional analysis of pancreatic β-cells in c-KitW-v mutant mice. Endocrinology 2007 ; 148 (11). 5520-5530. (Pubitemid 350012638)
10. Hagerkvist R., Makeeva N., Elliman S., et al. Imatinib mesylate (Gleevec) protects against streptozotocininduced diabetes and islet cell death in vitro. Cell Bio Int 2006 ; 30: 1013-1017. (Pubitemid 44781307)
11. Hagerkvist R., Jansson L. and Welsh N. Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin Sci 2008 ; 14: 65-71.
12. Louvet C., Szot GL, Lang J., et al. Tyrosine kinase inhibitors reverse type 1 diabetes in non-obese diabetic mice. PNAS 2008 ; 105 (48). 18895-18900.
13. Oxelmark E. and Hornberg JJ Finding the way in the jungle of kinase drug targets. Drug Discov Today: Technol 2008 ; 4 (3-4). e91 - e95.
14. Wilhelm S., Carter C., Lynch M., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2007 ; 5: 835-844.
15. Prunotto M., Bosco M., Lorenzo D., et al. Imatanib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta. Lung Cancer 2009 ; 64 (2). 244-246.
16. Radulovic S. and Bjelogrlic SK Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON 2007 ; 12 (1). S151 - S162.
17. Coluccia AML, Cirulli R., Neri P., et al. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 2008 ; 112 (4). 1346-1356.